|Articles|August 1, 2003

Targeting Melanoma

Chicago - Targeted drug therapy, a rational approach to the treatment of malignant melanoma, offers a number of targeted agents currently in development, according to Scott Saxman, M.D., senior investigator, Cancer Therapy Evaluation Program, National Cancer Institute.

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Latest CME

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Adaptive Learning

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Corey Cutler, MD, MPH, FRCP(C); Amin M. Alousi, MD; Mehdi Hamadani, MD; Anna Sureda, MD, PhD

Targeting Melanoma

Latest CME

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Trending on Dermatology Times

FDA Accepts sBLA for OnabotulinumtoxinA in Masseter Muscle, Pursuing Fifth Aesthetic Indication

Zasocitinib Shows High Rates of Scalp Psoriasis Clearance Through Week 24

From Wound Care to Aesthetics: How Conexeu Plans to Capitalize on the Bio-Regeneration Market

HS Case Study: Recognizing Moderate Disease in an Adolescent

AAD Pediatric AD Guidelines Back Roflumilast, Ruxolitinib, Tapinarof